Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Poloxamer 182 stands as one of many block copolymers that changed the face of drug formulation and delivery over the last fifty years. As research teams in the middle of the twentieth century started searching for excipients that could solve complicated solubility and stability challenges, the development of poloxamers emerged as a breakthrough for both pharmaceutical labs and production plants. The original patent work came out of academic and industrial collaborations, giving rise to a structure based on repeating units of ethylene and propylene oxides. Each iteration brought tweaks in the chemical sequence and block lengths, resulting in grades tailored for different uses, with number 182 finding its spot thanks to particular balance of molecular weight and hydrophilic-lipophilic properties. Regulatory agencies such as the British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopeia (USP) picked up on its reliability early, helping to drive widespread industry acceptance.
Poloxamer 182 in the pharmaceutical grade format lives up to high purity standards that keep drugs safe, stable, and effective. It’s not one of those compounds you find in only one kind of medicine. Instead, companies use it for its surface-active abilities—the very traits that chemists aimed for during its invention. Poloxamer 182 appears in both aqueous and semi-solid formulations, often handling tough tasks like improving drug dissolution or keeping separate ingredients from separating out over time. This grade, carrying certifications from BP, EP, and USP, gets tracked from batch to bottle, which makes it a trusted ingredient not just for drug makers, but for personal care and household product producers, too.
Visually, Poloxamer 182 usually appears as either a white powder or a soft waxy solid, depending on storage conditions and manufacturing process. It has minimal odor and melts at temperatures that don’t damage sensitive drug ingredients. As for chemical properties, its block copolymer structure brings both hydrophilic and hydrophobic sections. That means it can steer water-soluble and oil-soluble molecules into a single, stable phase. Molecular weight hovers around 2750 to 3350, with polyoxyethylene content close to 80%, giving it a high hydrophilic-lipophilic balance (HLB) value. Its solubility profile gets a lot of attention from formulators: it dissolves well in water and ethyl alcohol but keeps tablets from sticking together during production.
Regulators expect a lot when it comes to specification sheets for pharmaceutical excipients. Every lot of Poloxamer 182 comes with a record of molecular weight distribution, pH in solution, residual solvents, and content of key chemical groups. Heavy metals must sit at undetectable levels, and organic impurities can’t stray from tight limits set by international pharmacopoeias. Labels clearly list batch numbers, storage recommendations (usually cool, well-ventilated, and dry), and expiration date. Allergen status and country of origin often appear as well, reflecting the global nature of today’s drug supply chain. The label also makes note of compliance with BP, EP, and USP guidelines, offering transparency for buyers.
Poloxamer 182 gets made using a base-catalyzed addition of propylene oxide and ethylene oxide to a starter molecule—typically a small diol. The process takes place in reactor vessels that allow careful control of temperature and pressure, since getting the right sequence and block length matters for its properties. Once the polymerization finishes, the raw material gets stripped of residual catalysts, then goes through a purification step. The final material undergoes drying and milling before packaging. Strict checks catch any off-spec batches before they leave the plant. All of this happens under GMP (Good Manufacturing Practices) oversight, reflecting the ingredient’s use in sensitive end products.
The backbone of Poloxamer 182 makes it stable during most physical and chemical stress that pharmaceutical formulations endure. That stability is one reason it gets used so much. Chemists have tried tweaking parts of its structure—swapping block lengths or adding functional groups—for research on new drug delivery routes, including injectable and transdermal systems. In pre-formulation experiments, the compound faces a string of aggressive conditions to test compatibility with active pharmaceutical ingredients (APIs) and preservatives. It can form micelles or help solubilize poorly soluble drugs, which shines a light on possible ways to improve drug absorption. Researchers sometimes peg other functional groups to the ends to make “activated” poloxamers for linking with peptides or targeting moieties, though these specialty versions haven’t made their way into mass-produced drugs yet.
Depending on supplier and region, Poloxamer 182 appears under several different names. Manufacturers often use “Lutrol,” “Pluronic,” or “Synperonic” as trade names, followed by a code designating block structure, yet all refer back to the same basic chemistry. In pharmacopoeias or regulatory filings, it goes by Poloxamer 182 with a CAS Registry Number that helps track it through supply chains. The synonyms don’t signal differences in purity or manufacturing, but relying on official documentation and supplier audits matters for quality assurance. The different names sometimes trip up purchasing agents, so sticking to a preferred supplier and explicit regulatory name cuts through confusion.
Every pharmaceutical production floor puts a premium on worker safety, especially with ingredients that get handled in bulk. Despite its widespread use, Poloxamer 182’s safety record stands strong. Workers still follow protective guidelines: gloves to reduce the risk of skin irritation, goggles to guard against accidental dust exposure, and fume hoods when weighing out large quantities. Material Safety Data Sheets (MSDS) lay out proper storage and spill cleanup—nothing out of the ordinary, but enough to keep any concerns in check. Audit trails back up supplier credentials, and lot traceability stands ready for any recall or investigation that could happen down the line. GMP-certified plants document everything, from cleaning regimens to operator training.
Poloxamer 182 may not star in public drug ads, but in the lab it gets respect for versatility. Drug formulators turn to it to keep suspensions stable, emulsify eye drops, and shape soft-gel capsules. Its ability to boost solubility for tricky APIs solves problems for both generic and innovative medicine launches. In creams and gels, it helps blend water and oil phases smoothly, cutting the greasy feeling patients dislike. It also finds use in animal health, diagnostics, and cosmetic sectors, always keeping to the same standards for purity and performance. The demand for faster, more predictable drug release keeps Poloxamer 182’s profile high among excipients.
Labs worldwide continue searching for better ways to deliver drugs—both new molecules and existing ones in improved forms. Poloxamer 182 comes up in research on nano-encapsulation, where its block structure helps shepherd hydrophobic drugs into water-based suspensions that patients can tolerate. Teams designing long-acting injectables sometimes mix Poloxamer 182 into depot formulations to control the steady drip of medication into the bloodstream. There’s work being done on using poloxamers in thermoresponsive gels, which solidify at body temperature—a game-changer for local delivery after surgery or wound care. Pilot studies report improved bioavailability using Poloxamer 182 as a solubilizing partner for oral and ophthalmic drugs, and researchers track its effects across stability, blood compatibility, and biodegradation rates.
No matter how promising a compound looks, safety studies provide the make-or-break checkpoint. Early toxicology tests on Poloxamer 182 set the stage for its broad adoption. Oral and dermal studies suggest minimal absorption and low acute toxicity. Chronic exposure tests in animals reported no significant issues, with rare side effects linked to very high doses far beyond normal pharmaceutical use. Regulatory dossiers describe it as generally regarded as safe (GRAS) when used as intended, yet ongoing research keeps an eye on metabolic pathways and possible byproducts, especially with long-term or high-load injectable uses. Human clinical trials involving poloxamers regularly log tolerability outcomes, offering more data points to keep risk assessments current.
The road ahead for Poloxamer 182 runs parallel to big questions in medicine—how to improve solubility, target drugs more precisely, and minimize patient side effects. As personalized medicine grows and biologics take a larger share of new therapies, excipients have to keep up. The adaptability of Poloxamer 182’s chemistry opens the door to new combinations, including potential uses in gene delivery or as part of smart drug-release systems. The focus in labs includes scaling up novel formulations without losing purity or performance. Environmental concerns add another twist, prompting process improvements to reduce waste and improve energy efficiency during production. Companies investing in R&D for improved excipients see Poloxamer 182 as a dependable building block that just may find itself in a wider range of therapies in years to come.
Pharmaceutical manufacturing pulls together a blend of chemistry, engineering, and a commitment to patient wellbeing. In this setting, Poloxam 182 BP EP USP Pharma Grade stands out because it solves challenges others can’t touch. Poloxam 182 is a nonionic surfactant, which means it helps oil and water get along in medicines. Good old experience with excipients like this reveals that they're often invisible to the patient, but absolutely vital for the medicine’s safety and usefulness.
Every medicine starts with an active ingredient, the bit that treats the condition. Yet, without proper helpers, these actives sometimes clump together, fall out of solution, or fail to reach the part of the body where they’re needed most. Poloxam 182 steps in as an emulsifier and solubilizer, making tough-to-dissolve drugs more available for the body to absorb. Drugs that treat cancer, infections, or inflammation often rely on this property. If a drug doesn’t dissolve, it rarely works as intended.
Another role for Poloxam 182 crops up in ointments, creams, and topical gels. In my time in hospital pharmacies, problems like poor absorption bring frustrated patients back to the counter. With Poloxam 182, creams hold their shape, spread evenly, and deliver medication just where you want it. Beyond dissolving actives, it also helps medicines break apart in the digestive system, kicking off the process of drug uptake. As someone who has seen patients struggle to find the right formulation, I recognize how one excipient can make or break a treatment.
Trust grows from reliability. The BP (British Pharmacopoeia), EP (European Pharmacopoeia), and USP (United States Pharmacopeia) labels on Poloxam 182 signal testing for purity and safety. For patients with chronic illnesses, and for pharmacists, this standard removes guesswork. I’ve seen the frustration when a generic or off-label formulation falls short; consistency stays at the core of patient trust.
Poloxam 182 helps overcome one of the trickiest hurdles in drug development: making new medicines practical for real-world use. The rise of complex biotech drugs and personalized medicine brings new solubility headaches. Poloxam 182 reduces these headaches by giving researchers more freedom to test creative drug delivery systems. Bioavailability improves and patient outcomes see a lift.
Some patients worry about additives in their medications. Transparent labeling and solid research into the long-term safety of excipients help ease these concerns. Manufacturers answer with high-grade, tested excipients like Poloxam 182, paired with clear information on sourcing and quality. As more advanced treatments roll out, open communication between healthcare providers and patients zones in on better results.
The push for safer, better-tolerated medications owes a lot to quiet helpers like Poloxam 182. As researchers tackle diseases that once seemed untreatable, the small touches behind the scenes get more important—not less. For those of us working on medicine’s frontlines, every improvement in solubility, stability, and reliability feels personal. Bridging science with compassion builds trust and, step by step, shapes stronger patient care.
Poloxam 182, known in the pharmaceutical world as a non-ionic surfactant, comes with a reputation for reliability in drug manufacturing and delivery. Its other names include block copolymer or polyethylene-polypropylene glycol. Plenty of patients never see or hear about this compound, but pharmacists and researchers trust it for consistent performance in tough conditions.
For a product to carry the Pharma Grade badge, it has to meet tight standards set by pharmacopoeias like BP (British Pharmacopoeia), EP (European Pharmacopoeia), and USP (United States Pharmacopeia). These standards cover both chemical and physical properties, pushing manufacturers to monitor what goes in and comes out of the process.
Poloxam 182 offers an average molecular weight around 2,500 to 3,800 Daltons, with a specific hydrophilic-lipophilic balance suiting it to aqueous and semi-solid formulations. Viscosity, pH, and melting point all get measured, not just to fill out paperwork but to guarantee stability and performance for the end-user. If the pH falls outside the allowed range or the solution shows unwanted cloudiness, the batch never makes it to a pharmacy shelf.
Pharma Grade demands a minimum purity of 98%. Manufacturers keep a vigilant eye out for residual solvents, heavy metals, or microbial contamination. Residual solvents like ethylene oxide or propylene oxide have to test below 1 ppm to satisfy pharmacopoeia guidelines. Ash content, a marker for inorganic residues, should not cross the 0.2% threshold. Those working in quality control know what it takes to keep the numbers low—every step from raw material sourcing to handling influences the end result.
Water content also gets a hard look, with the right level sitting below 1%. Too much moisture invites degradation and instability, so the compound stays dry and safe. Purity testing checks for polyoxypropylene, polyoxyethylene content, and polydispersity—the version that lands in a laboratory should show near-perfect consistency batch after batch.
My years around compounding chemists taught me the cost of shortcuts. Lax purification can introduce chemicals that provoke adverse reactions or compromise product shelf life. The trusted protocols in BP, EP, and USP aren’t empty bureaucracy—those books reflect real-world mishaps, lawsuits, and recalls. Each passing decade brings stiffer rules, and for good reason. Delivering injectable drugs with unchecked levels of contaminants has ended in tragedy before.
Batch certificate reviews aren’t just box-ticking—sometimes, only a few micrograms of stray impurity create big problems for immunocompromised patients. Regulators push for traceability, so if a contaminant crops up in a patient, the source gets tracked back to a lot number and, eventually, to the hands that handled the raw materials.
Facilities championing product quality invest in validated processes: closed systems, filtered air, and rigorous cleaning cycles. Employee training matters just as much—a skilled technician with a sharp eye often catches things machines miss. Random batch testing, unannounced audits, and digital documentation help close the last loopholes.
Companies that collaborate openly with regulatory bodies foster a culture that puts patient safety above production speed. Instead of aiming for the bare minimum required by law, those who strive for higher purity, improved process controls, and regular third-party audits stand apart. In this space, reputation hinges on keeping error rates down and transparency up.
Pharmaceutical grade excipients don’t all measure up the same. Some only check the basics for purity, but to serve today's patient safety demands, true compliance means matching up with recognized pharmacopeias: British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopeia (USP). Poloxam 182, a synthetic nonionic surfactant, often pops up in discussions about pharmaceutical standards. Many formulation labs ask if it really satisfies the full regulatory checklist laid out by major authorities.
Consulting the official compendia clarifies what "pharma grade" promises. BP, EP, and USP each define their quality specs, focusing on aspects like purity, residue on ignition, molecular composition, and microbial limits. For Poloxam 182, matching these criteria isn’t just an academic issue. Any deviation—whether leftover solvents or variable polymer structure—can affect the way a final drug behaves. Quality control teams perform routine batch analysis, not only relying on certificates but conducting their own validation. This attitude saves time and stress in the long run because regulatory agencies don’t settle for shortcuts.
Personal experience in pharmaceutical QA taught me how documentation can trip up suppliers. No matter how clean the sample looks, complete traceability and lot consistency matter more. Sourcing Poloxam 182 that fails to provide a full chain of regulatory test results slows down the development cycle or, worse, results in product recalls. High-quality suppliers share finished testing data on demand, including confirmatory analysis that follows USP <761> for viscosity or BP guidance on heavy metals.
Regulators like the FDA and EMA have clamped down over the past decade after too many quality lapses. A product like Poloxam 182 must clear audits covering everything from identity (using infrared spectroscopy or NMR) to specific impurities that could build up in patients over time. For oral and topical medicines, excipients without solid compliance history increase the odds of batch rejections. Stakeholders in formulation, production, and clinical development all share risk if an ingredient falls short. Every time an inspection finds missing paperwork or the test results fail an EP microbial count, projects lose money.
Looking at market recalls between 2018-2023, issues involving excipients like Poloxam often trace back to incomplete regulatory vetting. Lessons learned underscore the point: skipping detailed review at the sourcing stage costs more down the road.
Manufacturers and buyers work together best when communications stay clear. Asking a supplier to provide all pharmacopeia-referenced test results before placing large orders can weed out low-quality sources faster. I have seen better, faster results using suppliers who openly list their compliance documents, offer real-time batch testing, and update their customers about changes in regulatory status. In this field, creating a file for each excipient—containing all BP, EP, and USP documentation—has kept audits smooth.
Suppliers making Poloxam 182 with proven regulatory standing often post their quality systems and test methods, giving buyers greater clarity. Regular exchanges between purchasing and quality assurance branches at both companies build trust and cut down surprises.
Patients rely on medicine for their health, so trust in every ingredient matters. Relying on Poloxam 182 means not just confirming it’s pharma grade but triple checking regulatory documentation aligns with BP, EP, and USP specs. Stronger supplier transparency, combined with vigilant internal quality practices, closes the gap between compliance and confidence.
Few things trip up a solid pharmaceutical process faster than poor storage. With Poloxam 182 BP EP USP Pharma Grade, slack habits can spoil batches, slow down lines, or create risk that nobody wants on their desk. This material, used widely for drug formulation, draws in moisture like a sponge in open air. Leave it out in a humid plant, and you’ll find clumps and caking that put equipment and product quality at risk. This isn’t something you shrug off — one careless afternoon can spoil your payload for good.
I’ve seen that a dry, cool area — with temperatures held between 15°C and 25°C — makes life easier for everyone involved. You want the humidity well controlled, ideally beneath 50%. Stack boxes away from windows, doors, and steam lines, since Poloxam 182 draws in moisture fast. In older storage rooms, you can’t always count on climate control. That’s where sealed drums come into play. I’ve relied on high-density polyethylene barrels lined with moisture barriers to keep powder dry through rainy seasons and warehouse temperature swings.
It’s worth mentioning that Poloxam 182 should always stay in its original packaging until just before use. Some operators cut open bags too early, hoping for faster access on the floor, only to watch the contents clump overnight. That’s lost material and wasted hours sieving it back to useable form. You save a lot more by opening only what the batch needs.
Bringing a pharmaceutical excipient from storeroom to production doesn’t leave much room for sloppiness. One dusty hand or an open bag on the wrong cart increases the risk of cross-contamination, especially on sites where other fine powders move around. I’ve learned that clean, dedicated scoops and closed transfer systems don’t just tick boxes. They keep batch records tidy and help pass audits without drama.
Pay attention to static build-up during handling. Poloxam 182 can cling to scoops and hoppers thanks to static, causing inconsistent dosing. Technical teams I’ve worked with use antistatic liners and grounded equipment. It’s worked well in both big plants and small research suites, making cleaning easier and reducing powder loss.
Personal protective equipment earns its place around Poloxam 182. Dust masks, gloves, and sometimes even goggles aren’t overkill, especially during large-scale transfers. Inhaling the fine particles can irritate airways; gloves keep dry hands and accidental rashes at bay.
Disposing of used packaging according to local rules is a must to avoid lingering residue in the workspace. Some teams set up a regular waste pick-up schedule to stay ahead of clutter. Labeled bins and clear signage help new staff avoid mistakes, especially in plants with multiple grade excipients stored side by side.
Good handling and storage relies on clear training. Written SOPs, refresher walkthroughs, and accessible reference sheets can bridge the knowledge gap, especially in fast-turnover shops. Investing in real storage rooms, not just the corner of the warehouse, keeps the risk of cross-contamination and loss much lower.
Poloxam 182 is not some mystery compound—it just asks for consistency and respect from the people working with it. Teams that get storage and handling right rarely scramble to fix avoidable problems. That consistency is the real difference between a headache-filled day and a clean batch record that everyone can stand behind.
Every time a new excipient appears in the pharmaceutical world, researchers and manufacturers pay extra attention. Every ingredient tells its own story inside a medicine, and Poloxam 182 is no exception. Poloxam 182 holds value as a non-ionic surfactant and stabilizer, bridging oil and water phases, or acting as a solubilizing agent. Because these functions matter directly to how a drug performs inside the body, knowing where safety issues might pop up can mean the difference between an effective therapy and a market recall.
Anyone who spent time in formulation labs has run across surprises as chemicals interact. Poloxam 182 shows broad compatibility with many common pharmaceutical actives and fillers. Its main role as a solubilizer makes it appealing for oral, topical, and sometimes injectable products. It mixes well with a variety of APIs, especially those that resist dissolving in water alone. Direct experience tells me: always run compatibility checks using real batch trials, not just paper studies.
I’ve seen formulas stumble when certain preservatives or antioxidants get mixed with non-ionic surfactants like Poloxam 182. For instance, strong acids or bases can shift the stability of this polymer. Sometimes, excipients that seem harmless alone can trigger precipitation or cloudiness if they don’t match pH or ionic strength. Glycerol, sorbitol, or simple sugars usually don’t cause issues, but some protein-based APIs need careful review for aggregation or denaturing. Sugar-based actives may crystallize, especially if the water content changes during storage.
The guidance always goes: run forced degradation studies, check every batch for appearance and solubility changes, and monitor stability at elevated temperatures. Stability with vitamins, minerals, or herbal extracts can be unpredictable. Years of working with non-ionic surfactants show that shelf-life predictions rarely match reality if you skip those exhaustive short-term studies.
Trusted sources like the European Pharmacopoeia and the United States Pharmacopeia set purity standards for pharmaceuticals. Poloxam 182 BP EP USP pharma grade gets held to those benchmarks. Still, purity doesn’t erase every risk. At high concentrations or with long-term exposure, some patients can experience gastrointestinal discomfort—this is more often seen with overuse in oral supplements than with prescription medicines. Skin irritation can occur in topical products, though non-ionic surfactants like this one are generally less reactive than anionic alternatives.
People with known allergies to polyethylene glycols may react to poloxamers. Careful patient screening and labeling make sense for these cases, especially as sensitivity sometimes turns up after repeat exposure. Accidental injection of large quantities—far above typical drug doses—can trigger kidney or liver challenges, though that’s rare in clinical settings. Every new formulation really does require a deep dive into animal and human safety data, even for grades deemed pure by pharmacopoeial standards.
The best approach never skips compatibility checks. Side-by-side testing with every excipient and active planned for the blend remains the gold standard. Temperature-cycling, light exposure, and humidity swings reveal incompatibilities well before a product hits shelves. Process validation, rigorous supplier audits, and checking certifications on each batch add peace of mind.
Open communication with suppliers builds trust and ensures documentation stays up to date. Changes to shipping, storage, or source materials can affect how Poloxam 182 behaves. Experience suggests that updating risk assessments with every formula tweak pays dividends. Safety hinges on checking every input at every step, not just trusting the grade or the brochure.
| Names | |
| Preferred IUPAC name | Poly(oxyethylene)-poly(oxypropylene)-poly(oxyethylene) block copolymer |
| Other names |
Pluronic L62 Synperonic PE-L62 Poloxamer 182 PEG-PPG-PEG Polyoxyethylene-polyoxypropylene block copolymer |
| Pronunciation | /ˈpəʊ.ləʊ.sæm/ |
| Identifiers | |
| CAS Number | 9003-11-6 |
| Beilstein Reference | 4031714 |
| ChEBI | CHEBI:53428 |
| ChEMBL | CHEMBL1201478 |
| ChemSpider | 10193497 |
| DrugBank | DB11125 |
| EC Number | 61827-42-7 |
| Gmelin Reference | Gmelin Reference: "87196 |
| KEGG | C14247 |
| MeSH | D020295 |
| PubChem CID | 121225734 |
| RTECS number | MD3475000 |
| UNII | 34I7P7ZD13 |
| UN number | UN number: Not regulated |
| CompTox Dashboard (EPA) | CompTox Dashboard (EPA) of product 'Poloxam 182 BP EP USP Pharma Grade' is "DTXSID20886046 |
| Properties | |
| Chemical formula | (C3H6O·C2H4O)x |
| Molar mass | 2750 g/mol |
| Appearance | White solid flakes or powder |
| Odor | Odorless |
| Density | 1.02 g/cm³ |
| Solubility in water | Soluble in water |
| log P | 1.78 |
| Vapor pressure | Negligible |
| Basicity (pKb) | 9.7 |
| Refractive index (nD) | 1.435 – 1.445 |
| Viscosity | 5000 to 6000 cP |
| Dipole moment | 1.1 D |
| Pharmacology | |
| ATC code | A06AD15 |
| Hazards | |
| Main hazards | May cause skin and eye irritation. |
| GHS labelling | GHS07, GHS hazard statement: Not classified as hazardous according to GHS, no signal word, no hazard pictogram |
| Pictograms | GHS07, GHS09 |
| Signal word | Warning |
| Hazard statements | No hazard statements. |
| NFPA 704 (fire diamond) | 1-1-0 |
| Flash point | > 212 °F (100 °C) |
| LD50 (median dose) | > 29700 mg/kg (rat, oral) |
| NIOSH | Not Listed |
| PEL (Permissible) | Not established |
| REL (Recommended) | 10 mg/m³ |
| Related compounds | |
| Related compounds |
Poloxamer 188 Poloxamer 407 Poloxamer 338 Polyethylene glycol Polypropylene glycol |
Chengguan District, Lanzhou, Gansu, China
